Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff Disease
October 13, 2020 07:00 ET
|
Axovant Gene Therapies
NEW YORK, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that...
Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 Gangliosidosis
October 09, 2020 07:00 ET
|
Axovant Gene Therapies
NEW YORK, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that...
Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial Officer
October 08, 2020 07:00 ET
|
Axovant Gene Therapies
Kristiina Vuori, M.D., Ph.D. is a leading genetics and cancer researcher who serves as President and Board member of Sanford Burnham Prebys Medical Discovery InstituteAppointment of Dr. Vuori...
Axovant Announces Positive Six-Month Follow-Up Data From Second Cohort of SUNRISE-PD Phase 2 Trial of AXO-Lenti-PD Gene Therapy
October 06, 2020 07:00 ET
|
Axovant Gene Therapies
• AXO-Lenti-PD was well-tolerated with no treatment-related serious adverse events at 6 months• 21-point mean improvement in UPDRS Part III “OFF” score, a 40% improvement from baseline, exceeding...
Axovant to Participate in Upcoming October Conferences and Provide AXO-Lenti-PD Program Update the Morning of October 6th
October 05, 2020 07:00 ET
|
Axovant Gene Therapies
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the Company will present...
Axovant and Viralgen Sign Strategic Gene Therapy Development and Manufacturing Partnership
September 15, 2020 08:00 ET
|
Axovant Gene Therapies
Partnership secures access to cGMP capacity and resources at Viralgen to support the development and commercialization of Axovant’s AAV gene therapy programs for GM1 and GM2 gangliosidosisPartnership...
Axovant Announces First Parkinson's Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences"
September 08, 2020 07:30 ET
|
Axovant Gene Therapies
- Parkinson’s Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30th, 2020, with leading movement disorder specialists NEW YORK and BASEL, Switzerland,...
Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 2020
August 11, 2020 07:00 ET
|
Axovant Sciences Ltd.
Data readouts for AXO-Lenti-PD and AXO-AAV-GM1 remain on-track for Q4 2020Completed 3-year manufacturing and supply agreement with Oxford BioMedica for AXO-Lenti-PDCompany had $55.5 million of cash...
Axovant Signs Three-Year Clinical Supply Agreement With Oxford Biomedica for Manufacturing and Supply of AXO-Lenti-PD
July 31, 2020 06:30 ET
|
Axovant Sciences Ltd.
NEW YORK and BASEL, Switzerland, July 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases,...
Axovant Announces Year-End Financial Results and Expected Key Clinical Milestones in Q4 2020
June 10, 2020 06:00 ET
|
Axovant Sciences Ltd.
Completed enrollment of cohort 2 of SUNRISE-PD Phase 2 study of AXO-Lenti-PD in Parkinson’s disease, with data from this cohort expected in Q4 2020Completed enrollment of low-dose cohort of Phase 1/2...